This study shall retrospectively evaluate the efficacy and safety of liquid-nitrogen based CT-guided cryoablation (CA) as a minimal-invasive technique for the curative treatment of primary breast cancer. A total of 45 female patients with 56 tumors were treated by CT-guided CA in analgosedation as an outpatient procedure. We used a liquid-nitrogen based system with a single cryoprobe and performed two freeze cycles with an intermediate thawing. The mean tumor diameter was 1.6 ± 0.7 cm. Follow-up was conducted via contrast-enhanced MR images of the breast. No complications were observed in all 56 ablations. Initial complete ablation was achieved in 100% of cases. Four cases of local tumor progression were reported, resulting in a rate of 8.9%, and 6 cases of intramammary distant recurrence at a rate of 13.3%. The extramammary tumor progression was observed in 7 patients at a rate of 15.6%. The mean overall survival was 4.13 years (95% CI: 3.7–4.5). The mean overall progression-free survival was 2.5 years (95% CI: 1.8–3.2) and the mean local progression-free survival was 2.9 years (95% CI: 2.3–3.6). Cryoablation is a safe and effective treatment for primary breast cancer tumors, which can be performed in analgosedation and as an outpatient procedure. However, potential for improvement exists and further evidence is necessary.
本研究旨在回顾性评估以液氮为基础的CT引导冷冻消融术作为一种微创技术，在原发性乳腺癌根治性治疗中的有效性和安全性。共纳入45例女性患者（56个肿瘤），在镇痛镇静状态下接受CT引导冷冻消融门诊治疗。采用液氮系统配合单根冷冻探针，实施两次冷冻循环并辅以间歇解冻。肿瘤平均直径为1.6±0.7厘米。术后通过乳腺增强磁共振成像进行随访。56次消融操作均未观察到并发症。初始完全消融率达100%。局部肿瘤进展4例（8.9%），乳腺内远处复发6例（13.3%），乳腺外肿瘤进展7例（15.6%）。患者平均总生存期为4.13年（95%置信区间：3.7-4.5），平均无进展生存期为2.5年（95%置信区间：1.8-3.2），平均局部无进展生存期为2.9年（95%置信区间：2.3-3.6）。冷冻消融术作为原发性乳腺癌的安全有效治疗手段，可在镇痛镇静状态下作为门诊手术开展，但仍存在改进空间，需进一步证据支持。
CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience
肿瘤(癌症)患者之家